Combination of bevacizumab (A) and pegylated-liposomal doxorubicin (PLD) (PLD-A) in sarcoma (SAR).

被引：0
|
作者：
Haddad, P. A.
Skubitz, K. M.
机构：
[1] LSU Hlth Sci Ctr, Shreveport, LA USA
[2] Univ Minnesota, Minneapolis, MN 55455 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9556
引用
收藏
页码：533S / 533S
页数：1
相关论文
共 50 条
  • [41] Pegylated liposomal doxorubicin (PLD) and weekly paclitaxel as first line therapy in metastatic breast cancer
    Fulfaro, F.
    Valerio, M. R.
    Cicero, G.
    Rinaldi, G.
    Intrivici, C.
    Pizzo, T.
    Crosta, A.
    Scibilia, C.
    Gebbia, N.
    ANNALS OF ONCOLOGY, 2006, 17 : XI10 - XI11
  • [42] Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
    J W Valle
    A Dangoor
    J Beech
    D J Sherlock
    S M Lee
    J H Scarffe
    R Swindell
    M Ranson
    British Journal of Cancer, 2005, 92 : 628 - 630
  • [43] Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains
    Song, Gina
    Suzuki, Oscar T.
    Santos, Charlene M.
    Lucas, Andrew T.
    Wiltshire, Tim
    Zamboni, William C.
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2016, 12 (07) : 2007 - 2017
  • [44] Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil™)
    Skubitz, KM
    Skubitz, APN
    ANTI-CANCER DRUGS, 1998, 9 (01) : 45 - 50
  • [45] Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
    Savani, Malvi
    Murugan, Paari
    Skubitz, Keith M.
    CLINICAL SARCOMA RESEARCH, 2019, 9
  • [46] Pegylated liposomal doxorubicin (PLD) as an active treatment option for desmoid tumor (DT) patients.
    Pang, Angela
    Macedo, Daniela Venancio Gouveia
    Carbini, Mariana
    Maki, Robert G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Implications of BRCA mutations on recurrent ovarian cancer outcome treated with pegylated liposomal doxorubicin (PLD)
    Safra, Tamar
    Borgato, Lucia
    Nicoletto, Maria Ornella
    Donach, Martin Edward
    Rolnitzky, Linda
    Geva, Ravit
    Peles, Sharon
    Pua, Thara
    Novetsky, Akiva
    Gabizon, Alberto
    Muggia, Franco
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [48] Weekly Docetaxel and Pegylated liposomal doxorubicin (PLD) in metastatic hormone refractory prostate cancer (HRPC)
    Pacilio, G.
    De Filippis, L.
    Simeon, D.
    De Domenico, R.
    ANNALS OF ONCOLOGY, 2005, 16 : 154 - 154
  • [49] Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD)
    Kushnir, C. L.
    Angarita, A. M.
    Havrilesky, L. J.
    Thompson, S.
    Spahlinger, D.
    Sinno, A. K.
    Tanner, E. J.
    Secord, A. A.
    Roche, K. L.
    Stone, R. L.
    Fader, A. N.
    GYNECOLOGIC ONCOLOGY, 2015, 137 (03) : 503 - 507
  • [50] Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
    Valle, JW
    Dangoor, A
    Beech, J
    Sherlock, DJ
    Lee, SM
    Scarffe, JH
    Swindell, R
    Ranson, M
    BRITISH JOURNAL OF CANCER, 2005, 92 (04) : 628 - 630
12345